2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)

Merck Sharp & Dohme LLC922 enrolled

Overview

The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay.

The duration of treatment is 4 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

922

Conditions

Postoperative Nausea and Vomiting

Interventions

MK0869, aprepitantDRUG

Comparator: ondansetron IVDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient is at least 18 years of age. * Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery). * Patient is scheduled to receive general anesthesia. * Patient is scheduled to receive postoperative opioids.

Outcomes

Primary Outcomes

Prevention of PONV in the 24 hours following end of surgery; Tolerability

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.